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Introduction
An old goal of natural complementary medical therapy has been
to aim at a long-term stimulation of natural resistance in order to
restrain cancer progression or improve defective immunological
conditions without toxic side effects. Mistletoe extracts were
applied to a large number of cancer patients because of their
modulatory effect on the natural immune system. By carefully
removing lectins, an essential group of components, from
mistletoe extracts, a significant reduction of their effectiveness
on several cellular immune parameters could be observed in
vivo (1). That is the reason why, for the last 14 years, biological
research of mistletoe extracts has focused on lectins.
Meanwhile, the quantitatively dominant lectin, Viscum album
agglutinin (VAA)-I has become available in a recombinant form
(rVAA). Other constitiuents of plant extracts such as viscotoxins
(2,3), poly- and oligosaccharides (4), flavonoids (5,6), chitin-
binding mistletoe lectin (7) and arginine have also been investi-
gated in connection with the effects of mistletoe extracts on the
host defense. However, little evidence has been found that these
substances contribute to the effects of mistletoe in vivo (8).
Structural Properties of Viscum album
Agglutinin (VAA)-I Are Important for the
Biological Activity of Mistletoe 
Plant Extracts
So far, mainly the mistletoe lectins and their sugar-binding 
B-chain have been considered as responsible for the
immunomodulatory effect of mistletoe extracts (1). Mistletoe
lectins are present in all mistletoe extracts in various concentra-
tions. Lectins are sugar-binding proteins that are able to
recognize and bind specifically the glycan part of glycoconju-
gates (such as glycoproteins, glycolipids, oligo- and polysaccha-
rides) (9) (Fig. 1). Lectins are widespread in all living organisms.
With regard to their physiological functions, however, there are
still numerous uncertainties. An important characteristic property
of lectins is their ability to agglutinate erythrocytes in vitro. That
is why they are frequently called ‘agglutinins’(e.g. phytohemag-
glutinin). For mistletoe lectins, a similar nomenclature is also
used: Viscum album agglutinin (VAA). The lectins are classified
according to their sugar specificity. This classification is based on
the monosaccharide that causes the greatest inhibition of the
lectin-induced agglutination of erythrocytes or the precipitation
of carbohydrate-containing polymers.
With regard to antigenity and chemical structure, there are
three similar lectins in mistletoe plants (10,11). The most
important and most often investigated lectin in mistletoe
extracts is the galactoside-specific VAA-I. As shown in Fig. 1,
it consists of a cytotoxic A-chain with a molecular weight of
29 kDa and a carbohydrate-binding B-chain of 34 kDa that is
responsible for its immunomodulatory efficacy. VAA-II
(according to an alternative nomenclature mistletoe II), with
galactoside as well as N-acetylgalactosamine specificity, and
mistletoe III, with N-acetylgalactosamine specificity, could be
degradation products of VAA-I in the plants themselves
(11–14). At present, the evaluation of mistletoe II and III varies.
Some teams have only found two groups of isolectin: galactoside-
specific VAA-I and N-acetylgalactosamine-specific VAA-II
(15). The structural analysis of VAA-I and its physical, chemical
and biological characteristics reveal many similarities to the
ricin molecule (11,16,17). The A-chain of VAA-I is a potent
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was found (23,24). The first cloning experiments for VAA-I
were performed by H. Lentzen, J. Eck, A. Bauer and H. Zinke
[European Patent, EP 075 1221 B1 (1995)]. Expression studies
in Escherichia coli allowed the production of the functionally
active recombinant A- and B-chains that were linked to an
active hololectin. The recombinant VAA (rVAA) showed similar
biological activity [cytotoxicity, RIP activity, induction of
apoptosis, selective binding, release of cytokines and stimula-
tion of natural killer (NK) function] to that found in the plant
extract (VAA-I) (25–27).
Biological Activity of Mistletoe 
Lectin (VAA-I)
The biological efficacy of mistletoe lectin can be regarded
basically as directly cytostatic as well as having an immunomod-
ulatory effect. In cultures of human peripheral mononuclear
cells (PBMCs), VAA-I can stimulate cytokine production as
well as programmed cell death (apoptosis) in approximately
the same concentration as in vivo (28–31). These effects are
interesting because plant lectins often imitate endogenous
lectins which can represent early mechanisms in the elimina-
tion of unknown cells showing altered sugar structure at the
membrane.
In Vitro Experimental Evidence for Cytotoxic,
Cytostatic and Apoptotic Effects
Is VAA-I treatment dose and time dependent in 
cell cultures?
If eukaryotic cells are incubated for 24 h in the presence of
VAA-I, this lectin already causes cytotoxic effects in the
picogram range as, for example, in the case of K562 (human
erythroleukemia) cells or EL-4 (mouse thymoma) cells (3,28).
In cultures of PBMCs. VAA-I also starts to have a cytostatic as
well as a cytotoxic effect at concentrations above 10 ng/ml if
incubated for 24 h (30). If the incubation time is shorter, this
toxic limit is naturally higher. It could also be proved that the
growth-inhibiting effect of mistletoe extracts and VAA-I in dif-
ferent cell cultures in vitro can be traced back to the induction
of programmed cell death (apoptosis) (28,29).
When human peripheral blood lymphocytes (PBLs) were
incubated for 24 h with VAA-I at a concentration ranging
between 1  g and 1 ng/ml, the flow cytometric analysis with
propidium iodide (PI) in hypotonic buffer solution and the
quantitative assessments of DNA fragments with terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP-digoxigenin
nick end-labeling (TUNEL) assay could confirm a dose-
dependent VAA-I-induced apoptosis at concentrations above
10 ng/ml (32). Monocytic leukemia (THP-1) cells and thymo-
cytes also showed apoptosis in the presence of VAA-I above 1
ng/ml. A 24 h incubation of PBLs with VAA-I above 10  g/ml
resulted in necrosis. The isolated A-chain caused similar apop-
totic effects; the B-chain was ineffective. These results indicate
that induction of inhibition of protein synthesis by the A-chain is
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ribosome inactivator. The carbohydrate-binding B-chain is
responsible for the internalization of the lectin molecule
(uptake into the cell). The B-chain binds terminal galactoside
residues on the cell membrane, preferring certain confirmations
(18). It is this chain that brings about the entrance of the whole
lectin molecule into the eukaryotic cells. The A-chain, on
account of its highly specific enzymatic efficacy, catalytically
inhibits protein synthesis in the 28S subunit of rRNA
(14,19–21). That is the reason why VAA-I, similarly to ricin,
abrin (a lectin from the red seed of Abrus precatorius), modec-
cin and volkensin, belongs to the type II family of ribosome-
inactivating proteins (RIPs) with numerous homologous
structures (11,22). In addition to the type II RIPs with two
chains, a large number of the single-chain type I RIPs, such
as gelonin (a glycoprotein from the indian plant Gelonium
multiforum) or trichosanthin (a cytotoxic protein from the roots
of the Chinese drogue Wangua Trichosantes kirolowii and
cucumeroides) have been described (22). They were isolated
from a variety of phylogenetically independent plant species so
that the RIPs (types I and II) obviously belong to an ‘old’
evolutionary development. Recently, the primary structure of
Figure 1. Viscum album agglutinin (VAA-I) consists of two chains. The 
A-chain (white) with a molecular weight of 29 kDa and with N-glycosidase
activity is a potent ribosomal inactivator. The sugar-binding B-chain (green)
with a molecular weight of 34 kDa is responsible for the immunomodulatory
effect of the molecule. Red colored parts of the B-chain indicate the sugar-
binding receptors. (The picture was kindly provided by Madaus Ag, Germany.)eCAM 2005;2(1) 61
responsible for the apoptotic effect of the whole lectin molecule.
PBLs showed variable sensitiveness to VAA-I-induced apopto-
sis: NK, CD19    CD8    CD4  cells (26). Activated lym-
phocytes (CD25 , CD69  and HLA-DR  cells) were also
more sensitive to lectin-induced apoptosis than non-activated
cells (unpublished data). In different lymphocyte populations,
selective modulation of Fas antigen by VAA-I indicates that
Fas antigen-activated signaling can at least partially play a role
in VAA-I-induced apoptosis (26).
What is the pathway of VAA-I-induced apoptosis?
In the early stage of apoptotic cell death, a phospholipid inver-
sion takes place. The phosphatidylserine expression is ascertain-
able by annexin-V binding. Thus it could be found that VAA-I
(100 ng/ml)-induced apoptosis changes into increasing necrosis
after 48 h (32). In cultures of U937 promonocytes, VAA-I
(30–100 ng/ml) causes an increased cytosolic Ca2 concentration
which, among other factors, is a sign of apoptosis (33). In addi-
tion, VAA-I could enhance the stimulating effect of histamine
(H1) and complement (C5a) on cytosolic Ca2  concentrations
that play an accelerating role in the regulation of apoptosis. In
Jurkat leukemic T cells, it was demonstrated previously that
VAA-I-induced apoptotis was linked to activation of caspase-8
but independent of death receptor signaling (34). Furthermore,
mechanistic investigations with the genetically defined p53 / 
and p53 /  murine tumour cell system show that breakdown of
the mitochondrial membrane potential and caspase-3 activation
occurred in a p53-independent manner on treatment with rVAA.
However, the rVAA-induced apoptosis leading to caspase-3-
activation requires an apoptosis-associated factor-1 (Apaf-1)-
dependent pathway (35). It could be shown that rVAA overcomes
a high apoptotic threshold and cooperates with ionizing radiation
in tumor cells that lack intact p53 and, therefore, may represent a
novel therapeutic approach for the treatment of cancer.
Recently it was found that VAA-I is a potent inducer of
human neutrophil apoptosis via caspase-3 activation (36).
VAA-I alters the mitochondrial transmembrane potential and
increases intracellular levels of reactive oxygen species (ROS).
Furthermore, the decrease of the expression of the antiapop-
totic Mcl-1 and caspase involvement in the degradation of
cytoskeletal paxillin and vimentin proteins in VAA-I-induced
neutrophil apoptosis have been described (37). Recently,
induction of apoptosis in activated neutrophils by VAA-I above
100 ng/ml concentration and inhibition of lipopolysaccharide
(LPS)-induced proinflammatory responses in vivo were
demonstrated (38). These data may provide further clinical
perspectives for future mistletoe therapy.
Not only lectins with RIP activity cause apoptosis. Griffonia
simplicifolia 1-B4 and wheat germ agglutinin (WGA) stimu-
late programmed cell death in cultures of different cell lines
(39). With regard to the apoptotic effect of lectin–sugar inter-
actions on the cell membrane, the question arises as to whether
this is only an in vitro phenomenon or whether it has thera-
peutic relevance. Further in vivo animal experiments are
necessary to answer these questions.
Investigations of Lectin-induced Gene Expression and
Secretion of Proinflammatory Cytokines
Can the proinflammatory cytokine production be
influenced?
The results of cytokine research with regard to mistletoe are
almost exclusively from in vitro data that cannot be directly
transferred to in vivo situations. In vivo, cytokines are active at
very low concentrations in a complex network. In vitro and
in vivo, effective immunomodulators can only bring about short-
term changes in serum concentrations of cytokines and only to
a very small degree (picogram range) (30). The investigation
of lectin-induced proinflammatory cytokines was also import-
ant because cancer patients often show decreased inflamma-
tory responsiveness. In 24 h culture of PBMCs, low and
non-toxic lectin concentrations (with an optimum between
1 and 10 ng/ml) stimulate the release of proinflammatory
cytokines such as interleukin (IL)-1, IL-6 and tumor necrosis
factor (TNF)-  dose dependently. D-Galactose, a monosaccha-
ride with the highest affinity for VAA-I, blocks TNF-  release
competitively. Mannose that shows no affinity for VAA-I has
no effect in comparable concentrations. These results confirm
that sugar–protein interaction mediated by the sugar-binding
B-chain is fundamental for the immunomodulating effect of
VAA-I. An enhanced expression of TNF-  mRNA was
induced in human monocytes and in macrophages from
endotoxin-resistant (C3H/HeJ) mice, if these cells had been 
pre-incubated with VAA-I for 2 h (40). After 24 h incubation
of human PBMCs with non-cytotoxic concentrations of VAA-I
(10 and 1 ng/ml), the expression of mRNA was measured for
a series of cytokines with the help of reverse polymerase chain
reaction (rPCR) (31) (Fig. 2). VAA-I induced gene expression
of IL-1  and  , IL-6, TNF- , interferon (IFN)- , granulocyte–
monocyte colony-stimulating factor (GM-CSF) and IL-10. In
contrast, no expression of IL-2 and IL-5 could be found. 
Non-cytotoxic concentrations of other mistletoe lectins (II and
III) also induced increased secretion of proinflammatory
cytokines in monocytes isolated from peripheral blood (41).
Which subsets of leukocytes are activated after VAA-I
priming in vitro?
So far, the investigation of mistletoe-induced cytokines leads to
the assumption that monocytes are the most important site of
origin. This hypothesis is supported by the fact (Fig. 3) that
monocytes can bind fluorescencently labeled molecules of
VAA-I with a considerably higher affinity than lymphocytes
(31). Thus lectin–sugar interactions on the cell membrane of
monocytes can play an important role in the proinflammatory
effect of mistletoe extracts. In cultures of monocytic THP-1
cells, VAA-I increased the concentrations of inositol phos-
phatase and phosphatidylinositol, indicating lectin-induced
signal transduction in monocytes (42). The preferential effect of
mistletoe extracts on the natural immune system is not restricted
only to monocytes. Granulocytes also show a higher affinity
for VAA-I than lymphocytes (31). VAA-I was shown to bindpreferentially to terminally  2–6-sialylated neolacto series
gangliosides from human granulocytes (43). In cultures of
lymphocytes, VAA-I increased the concentration of HLA-DR 
lymphocytes and NK cells and induced gene expression of
cytokines (31). When the ED50 values of lectin-binding rates of
different lymphocyte subpopulations were compared, the follow-
ing sequence was found: NK, CD19    CD8    CD4  (26).
The in vitro ability of mistletoe extracts to stimulate proin-
flammatory cytokines was also used for the biological standard-
ization of medicaments. In a skin model system, VAA-I 
(0.75–8 ng/ml) given in isolated form or in mistletoe extracts
caused increased release of IL-1 and IL-6 dose dependently (44).
In a model of multilayered keratinocytes, similar results were
found (45). Proinflammatory cytokines play a significant role in
the regulation of innate immunity. They can be at least partially
responsible for mistletoe-induced immunomodulatory effects.
In addition, another member of the cytokine network, IL-12
that also regulates innate immunity, was investigated. In cul-
tures of PBMCS, VAA-I increased the secretion of total IL-12
and its active p70 form (27). IL-12 is not only important for the
well-known control of NK mechanisms, but it also seems to
have a key position with regard to the regulation of the balance
between cellular and humoral immunity (46) that may be
altered as a consequence of many diseases, for instance
advanced cancer (46,47). On the other hand, VAA-I could
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Figure 2. Cytokine gene expression in cultured PBMCs (31). After 24 h of
culture in the absence (lane 1) and in the presence of 10 ng/ml (lane 2) or
1 ng/ml (lane 3) VAA-I and 1.5  g/ml PHA (lane 4), total cellular RNA was
extracted, reverse-transcribed and assayed in 35 cycles of PCR in the presence
of the indicated pairs of primers. (The figure was kindly provided by S. Karger
AG, Switzerland.)
Figure 3. Binding of fluorescein isothiocyanate (FITC)-conjugated VAA-I to different leukocytes in lysed whole blood of one donor as a representative example.
Percentages of positively stained lymphocytes, granulocytes and monocytes are shown as a shift towards the right in comparison with fluorescence obtained with
control (31). The percentage of fluorescence-shifted cells is given in each histogram. As a negative control, unlabeled VAA-I at 100-fold concentration was used.
(The figure was kindly provided by S. Karger AG, Switzerland.)eCAM 2005;2(1) 63
modulate the IL-15-induced neutrophil responses. A higher
concentration of VAA-I (100 ng/ml) was found to reverse the
ability of IL-15 to delay neutrophil apoptosis (48). On the
basis of these results, in vivo model experiments may possibly
pave the way for clinical application.
In Vitro Effects of VAA-I on Cellular Parameters of
Innate immunity and on Hemopoietic Progenitor Cells
of Bone Marrow
More than 15 years ago, the discovery was made that VAA-I
and its B-chain stimulate the phagocytotic activity of human
leukocytes (49). As mentioned earlier, monocytes and granu-
locytes show a higher affinity for VAA-I than lymphocytes
(31). VAA-I induces a greater release of oxygen radicals from
granulocytes than other lectins (50). The influx of Ca2  ions
plays a role in the O2 formation of activated phagocytic cells.
It was demonstrated that VAA-I stimulates the uptake of Ca2 
into granulocytes. These results support the possibility of a
lectin-induced galactoside-specific activation of the biosignal-
ization (51). VAA-I in combination with other cytokines
in vitro is often more effective than the lectin alone. For example,
VAA-I in combination with suboptimal concentrations of IL-2
and IL-12 induced an additive increase of NK cytotoxicity of
human PBMCs or rat spleen cells against NK-sensitive target
cells (27). These results were confirmed by other investigators
(52) who found a synergism between IL-12 and VAA-I in the
induction of lymphokine-activated killer (LAK) activity.
Lectin-induced enhancement of IL-12 may indicate the selec-
tive activation of the Th1 pathway in dendritic cells derived
from CD16  macrophages. In culture of hematopoietic
progenitor (CD34 ) cells originating from bone marrow, VAA-I
in combination with other hematopoietic growth factors [stem
cell factor, IL-3, granulocyte colony-stimulating factor (G-CSF),
macrophage colony-stimulating factor (M-CSF) and erythro-
poetin] also caused significantly increased proliferation in a
synergistic manner (53).
In Vivo Effects of Mistletoe Extracts and VAA-I on
Cellular Parameters of the Natural Immune System 
in an Animal Model, Healthy Volunteers and 
Cancer Patients
Characteristic dose dependency of VAA-I was found in differ-
ent cell cultures in vitro (see above). The number and ratio of
circulating lymphocyte subpopulations and their activation
markers were investigated using different VAA-I concentra-
tions. With regard to cellular immunological reactions in vivo,
a bell-shaped dose–response curve of VAA-I and mistletoe
extract could be observed (1,54–56) (Fig. 4). A single injection
of pure VAA-I (0.25–1 ng/kg) into rabbits dose dependently
enhances their temperature as well as the number and phago-
cytitic activity of granulocytes, the cytotoxic activity of NK
cells and the number of large granular lymphocytes (LGLs) in
peripheral blood (1). The maximum effect was found at
0.8 ng/kg body weight (1). In humans, the optimal effect was
within the range of 1 ng VAA-I/kg (57), this dose being far
below the toxic limit. The 50% lethal dose (LD50) for mice
lies within a few hundred  g/kg (58). Experiments with
mistletoe extracts standardized with regard to lectin activity
suggest that an immunological stimulation induced by an
optimal lectin dose (1 ng VAA-I/kg) can only be repeated
after 3 days without therapy (57). In rats, recombinant mistle-
toe lectin (rVAA) also showed a bell-shaped dose–response
relationship when the activity and frequency of NK cells in
the blood were investigated after a single injection of
various doses (27) (Fig. 4) Similar results were published
recently with Argentine mistletoe Ligaria cuneifolia applied
in a murine model (59).
In the case of cancer patients, subcutaneous injections of
mistletoe preparations with a lectin dose of 1 ng VAA-I/kg
twice a week led to an elevation of cytotoxic activity and
frequency of peripheral NK cells (CD3 /CD16 56 ) and
Figure 4. Immunological responses after a single i.v. injection of rVAA in
rats (27). Six randomized groups each containing eight animals (Wistar rats)
were treated once with placebo or with various doses of rVAA. Blood samples
were collected before and 48 h after a single injection. After 2 days, all
animals were sacrificed. Upper columns: NK-mediated cytotoxicity of spleno-
cytes against YAC-1 cells (after 48 h) expressed as mean relative increase
( SEM) in the number of 107/LU33 of each group as ratios to the control. One
LU33 is defined as the number of lymphocytes required for 33% lysis of
2   104 target cells extrapolated from regression line analysis of the specific
cytotoxicity of four different effectors: target cell ratios (100:1, 50:1, 25:1 and
10:1). Thereafter, the number of 107/LU33 is calculated. Lower columns: mean
relative enhancements ( SEM) in absolute counts of LGL in peripheral blood
expressed as ratios to baseline values. Each value of the treated groups was
compared with the control and statistically analyzed (*P   0.05; **P   0.01;
***P   0.002).LGLs (56). In addition, an increase in peripheral lymphocytes,
T cells and Th cells, enhanced expression of CD25  and 
HLA-DQ  activation markers, and increased concentration of
acute phase proteins and of complement factor C3 could be
observed (60–63). In view of the lack of controlled clinical
investigations on the immunomodulating efficacy of VAA-I and
mistletoe extracts that were indispensable for further clinical
trials, we carried out four randomized crossover double-blind
pilot studies with healthy volunteers. For the first and second
study, the lectin preparation was isolated from mistletoe extracts.
The effect of this concentrated lectin preparation on different
lymphocyte subpopulations (CD3 , CD4 , CD8 , CD3 /
CD16 56 , CD3 CD25 , CD3 CD69  and CD3 HLA-DR )
and the cytotoxic activity of NK cells was measured in the
peripheral blood of nine and eight persons, respectively.
In contrast to significant lectin-induced increases in the number
of lymphocytes and LGLs in animal models, healthy persons
did not show any significantly different reactions with regard to
the lymphocyte subpopulations mentioned above or NK activ-
ity with the same lectin concentration as compared with saline
controls (64). However, when comparing mistletoe-induced
reactions with the pre-treatment values, the increases in concen-
tration and activity of the NK cells were found to be significant
only after lectin application. Because of the considerable intrin-
sic variations of these parameters after placebo treatment,
further randomized crossover double-blind pilot studies with
six and eight healthy persons, respectively, were made with a
parameter that could be assessed more rapidly following the
injection. In addition,VAA-I freshly isolated from the plant was
given to diminish the negative effect of a possible lectin insta-
bility originating from the commercial extract.
The priming of the granulocytes was tested 5 h after the
injections. In both studies, a significant increase in the priming
of granulocytes 5 h after the injection of purified VAA-I was
found as compared with placebo controls (Table 1). As men-
tioned above, an immunological stimulation induced by an
optimal lectin dose can only be obtained again after 3 days
without therapy (57). As a consequence of the results with low
doses, the question arises as to whether a regular application of
the immunologically active low-dose extracts twice a week can
lead to a long-term increase in the cellular parameters of innate
immunity. Various independent observations were able to
confirm this suggestion (65,66).
Cancer patients often show a correlation between clinical
progress, quality of life and responses of the cellular parameters
of the natural immune system. Heiny and Beuth assessed the
plasma level of  -endorphin together with several immune
parameters during the immunologically optimized mistletoe
treatment of cancer patients. Significant correlations were found
between the  -endorphin level, the mistletoe lectin-induced
immunological reactions and the clinical progress (67,68). As an
endogenous opioid,  -endorphin levels in plasma correlated
with well-being and relief of pain in these patients.
In Vivo Effect of VAA-I on Proliferation and Apoptosis
of Murine Thymocytes
Can we also detect apoptotic effects of VAA-I in vivo?
In a recent study, the short- and long-term in vivo effects of
VAA-I on thymocyte subpopulations and peripheral T cells
were tested using a murine (Balb/c) model (69). The changes
of thymocyte subpopulations: CD4 CD8  double negative
(DN), CD4 CD8  double positive (DP), CD4  or CD8  sin-
gle positive (SP) and mature peripheral T cells were monitored
after a single or repeated injections with 1 and 30 ng/kg VAA-I.
A single injection of different doses of VAA-I did not cause
significant alterations in the absolute thymocyte cell count or
in the DN, DP and CD4  cell number (Table 2). Only the
CD8  thymocyte number increased significantly. In the long-
term trial, Balb/c mice were treated with the same doses of
VAA-I lectin   dexamethasone (DX) twice a week for 3 weeks.
At 72 h after the last injections, the total thymocyte cell
count in the thymus increased significantly after both lectin
doses. As demonstrated in Table 2, with the exception of CD4 
cells, all investigated thymocyte subpopulations (DN, DP and
CD8  cells) increased significantly after long-term treatment
with 30 ng/kg VAA-I. A dose of 1 ng/kg lectin also caused an
increase in all cell populations, but significant growth could be
measured only in the CD8  thymocyte population, indicating
that CD8  thymocytes in both short- and long-term studies
were found to be more susceptible to lectin-induced prolifera-
tion in the thymus (69).
How does the relationship between glucocorticoids and
VAA-I affect murine thymocytes?
Since it is well known that DX causes considerable reduction
of the thymocyte count, the effects of VAA-I treatment on
short (24 h) and long-term (twice a week, for 3 weeks) DX
(1 mg/kg body weight) therapy were also investigated in
parallel to the lectin-induced alterations. As expected, DX treat-
ment alone induced a significant reduction in the total number
of thymocytes in both cases. This DX-induced reduction of
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Table 1. Double-blind crossover studies in healthy volunteers
First trial Confirmatory
(n   8) study (n   6)
Placebo VAA-I Placebo VAA-I
Relative increases in
priming of PMN
5 h 0.92 (0.25) 1.94** (0.59) 1.04 (0.31) 3.56** (1.33)
24 h 0.85 (0.29) 1.32* (0.43) 0.8 (0.69) 1.84* (0.88)
LGL/ml
0 h 656 (163) 540 (173) 639 (205) 555 (204)
24 h 472 (137) 1052* (364) 578 (196) 1131* (395)
Average increases (95% confidence intervals) of oxidative reactions of
circulating polymorphonuclear neutrophils (PMNs) were assessed 5 and 24 h
after a single injection of 1 ng VAA-I/kg body weight or of salt solution in
comparison with pre-treatment values. The absolute number of LGLs in
peripheral blood was also tested.
Statistical analysis was carried out between the treated group and the placebo
group with the help of a paired t-test (*P   0.05; **P   0.01).eCAM 2005;2(1) 65
thymocyte cell count was significantly less if DX was injected
in combination with VAA-I. As shown in Table 2, all investi-
gated thymocyte subpopulations (DN, DP and SP) showed
significant elevation if DX was combined with VAA-I (69).
The apoptosis of the murine thymocytes was detected by
flow cytometry using PI and annexin V staining. At 24 h after
a single injection of 30 ng/kg VAA-I, CD4  and CD8  SP thy-
mocyte subpopulations showed 2- and 1.7-fold enhancements,
respectively, in the frequency of apoptosis compared with
negative control values. In the long-term trial, only 30 ng/kg
VAA-I (72 h after the last injection of a treatment for 3 weeks)
caused a significant increase (54%) in the percentage of apop-
totic thymocytes.
Modulating the Effect of VAA-I on the 
Dexamethasone-induced Apoptosis and Glucocorticoid
Receptor Level in Balb/c Thymocytes
In another recent study (70), the effect of VAA-I treatment on
DX-induced apoptosis of thymocytes in Balb/c mice was
tested. The number of early apoptotic cells was detected with
annexin V staining while the late apoptotic cells were identi-
fied according to their PI incorporation into DNA using flow
cytometry. The expression of glucocorticoid receptor (GCR) in
DN, DP and CD4 or CD8 SP cell populations was assessed.
The additive effect of lectin on DX-induced apoptosis of
thymocytes consisted of two different actions of VAA-I and
DX. A 1 day treatment with VAA-I caused enhanced apoptosis
in SP mature cells, whereas the apoptotic effect of DX was
directed mainly towards immature DN and DP cells (62).
Treatment with 30 ng/kg VAA-I for 4 days elevated the GCR
level (mean fluorescence intensity) in DP thymocytes (70).
Lectin treatment for 21 days caused  20% elevation of GCR
expression in all thymocyte subpopulations (DN, DP, CD4 
and CD8 ). These results suggest that VAA-I may alter the
sensitivity of thymocytes to glucocorticoids and this effect
may play a role in the bell-shaped dose–response curve of the
lectin-induced immunological effects.
Conclusions
With regard to the biological and preclinical research of
mistletoe lectin, two essentially different effects must be con-
sidered: cytostatic/apoptotic and immunomodulatory effects.
Both effects showed a very strong Gaus-type dose dependency.
Low doses of VAA-I supported the T-lymphocyte differenta-
tion and maturation, in contrast to the increased VAA-I dose
both in vitro and in vivo in different experimental models. This
basic biological effect may support a long-term therapeutic
modulation of the natural immune system which is associated
with a protective effect in combination with toxic modalities of
various therapies and with improved quality of life.
Higher doses of VAA-I with cytostatic/apoptotic effects
could suggest new perspectives to modulate the balance
between cell growth and programmed cell death therapeuti-
cally. In addition, inhibition of proinflammatory responses by
higher doses of lectin may provide further clinical perspectives
in the future.
It could be shown that VAA overcomes a high apoptotic thresh-
old and cooperates with ionizing radiation in tumor cells that lack
intact p53. This may represent a novel therapeutic approach.
At present, it is difficult to judge of the clinical benefit of
mistletoe lectin, and in many aspects it is not feasible, but
growing evidence (71–81) suggests that VAA-I can improve
the clinical situation of patients with a decreased responsiveness
of the natural immune system. In addition, further experimen-
tal research is required to establish the favorable effect of
lectin during the treatment of diseases in which programmed
cell death is defective.
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